Amedisys, Inc. (AMED)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AMED or CHE: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Amedisys (AMED) and Chemed (CHE). But which of these two companies is the best option for those looking for undervalued stocks?
Will Amedisys (AMED) Beat Estimates Again in Its Next Earnings Report?
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AMED vs. CHE: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Amedisys (AMED) and Chemed (CHE). But which of these two stocks is more attractive to value investors?
Amedisys (AMED) Moves to Buy: Rationale Behind the Upgrade
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AMED or CHE: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE). But which of these two stocks presents investors with the better value opportunity right now?
AMED vs. USPH: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Amedisys (AMED) or U.S. Physical Therapy (USPH). But which of these two stocks is more attractive to value investors?
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.
Compared to Estimates, Amedisys (AMED) Q2 Earnings: A Look at Key Metrics
The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amedisys (AMED) Q2 Earnings and Revenues Top Estimates
Amedisys (AMED) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.37 per share a year ago.
Here's Why Amedisys (AMED) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMED or USPH: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH). But which of these two companies is the best option for those looking for undervalued stocks?
AMED vs. USPH: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Amedisys (AMED) or U.S. Physical Therapy (USPH). But which of these two companies is the best option for those looking for undervalued stocks?
